Shannon M. Rotolo

Shannon M. Rotolo

Auto-generated profile, based on publicly available information

Shannon M. Rotolo

Department of Pharmacy, University of Rochester Medical Center, Rochester, NY, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
SHSuyeon Heo
Suyeon Heo
DYDavid C. Young
David C. Young
JSJulie Safirstein
Julie Safirstein
BBBrian Bourque
Brian Bourque
MAMartine H. Antell
Martine H. Antell
SRShannon M. Rotolo
Shannon M. Rotolo

1 September 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
SRShannon M. Rotolo
Shannon M. Rotolo
SDStephanie Duehlmeyer
Stephanie Duehlmeyer
SSSarah M. Slack
Sarah M. Slack
HJHollyann R. Jacobs
Hollyann R. Jacobs
BHBrian Heckman
Brian Heckman

22 July 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RRRegina Royan
Regina Royan
TPTricia Rae Pendergrast
Tricia Rae Pendergrast
MRMarina Del Rios
Marina Del Rios
SRShannon M Rotolo
Shannon M Rotolo
NTN Seth Trueger
N Seth Trueger
VAVineet M Arora
Vineet M Arora
Social media is an important tool for disseminating accurate medical information and combating misinformation (ie, the spreading of false or inaccurate information) and disinformation (ie, spreading misinformation with the intent to deceive). The prolific rise of inaccurate information during a global pandemic is a pressing public health concern. In response to this phenomenon, health professional amplifiers such as IMPACT (Illinois Medical Professional Action Collaborative Team) have been created as a coordinated response to enhance public communication and advocacy around the COVID-19 pandemic.

7 September 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
BHBrionna N. Hudson
Brionna N. Hudson
HJHollyann R. Jacobs
Hollyann R. Jacobs
APAlexander Philbrick
Alexander Philbrick
XZXiaolong A. Zhou
Xiaolong A. Zhou
MSMichelle M. Simonsen
Michelle M. Simonsen
SRShannon M. Rotolo
Shannon M. Rotolo

21 August 2021 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
SRShannon M. Rotolo
Shannon M. Rotolo
SJShikha Jain
Shikha Jain
SDSerena Dhaon
Serena Dhaon
JDJack K. Dokhanchi
Jack K. Dokhanchi
EKElzbieta Kalata
Elzbieta Kalata
VAVineet M. Arora
Vineet M. Arora

1 January 2021 in The Journal of Pediatric Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
HFHaley M. Fox
Haley M. Fox
SRShannon M. Rotolo
Shannon M. Rotolo
Biologic agents, including anti-immunoglobulin E (omalizumab) and anti-interleukin 5 (mepolizumab), target different mediators involved in the inflammatory process and may work synergistically to decrease symptoms in patients with severe asthma. Here we describe a 12-year-old female on 2 biologic agents, omalizumab and mepolizumab, to control severe persistent asthma. Omalizumab was started years earlier with an initial response; however, her asthma again became uncontrolled and mepolizumab was added. Both biologics were administered concomitantly for over 6 months with marked improvement of asthma symptoms without significant side effects. A combination of biologic agents may be a potential therapy for pediatric patients with severe persistent asthma that remains uncontrolled on a single agent.